Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Gwo Xi Stem Cell Applied Technology Co. , Ltd TWD 2.93, price TWD 21.95, upside -86.7%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Gwo Xi Stem Cell Applied Technology Co. , Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
10‑month range 18.80 TWD – 28.15 TWD · fair‑value band 2.19 TWD – 4.38 TWD · the 21.95 TWD price screens above the 2.93 TWD fair value. As of Sep 24, 2026.
Follow Gwo Xi Stem Cell Applied Technology Co. in your weekly email
Every Wednesday you see whether Gwo Xi Stem Cell Applied Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs.
Show more
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.
Stock analysis
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) currently trades at 21.95 TWD, while our model-based Fair Value estimate is 2.93 TWD, implying the stock looks roughly 649.1% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 2.19 TWD (bear) to 4.38 TWD (bull), the price of 21.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Gwo Xi Stem Cell Applied Technology Co. , Ltd reported revenue of 187M TWD in FY2025 versus 243M TWD in FY2021, a compound −6.3%/yr. Reported net income was −80.5M TWD in FY2025.
Key figures
Market cap 2.1B TWD (≈ $66.1M) · P/S ratio 10.0 · EPS (TTM) −0.8400 TWD · Net margin −43.1% · Return on equity −13.0% · Return on assets (EBIT) −8.5% · Operating margin −45.5% · Revenue (TTM) 187M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −87%, 6704 screens richer than that median.
Fair Value models
Bear 2.19 TWDFair Value 2.93 TWDBull 4.38 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.4/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+10.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−39.5% (2020) → −39.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Gwo Xi Stem Cell Applied Technology Co. , Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score40 · Below median
Fair Value upside−86% · Bottom 25%
Profitability
Return on assets−5% · Above median
Net margin (TTM)−43% · Bottom 25%
Operating margin (TTM)−45% · Bottom 25%
Growth and dividend
Revenue growth2% · Above median
Balance sheet
Debt / equity0.42× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.11× · Cheapest 25%
P/S (TTM)0.34× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)12· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)79· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Gwo Xi Stem Cell Applied Technology Co. , Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6704
Frequently asked questions
Is Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2.93 TWD versus a price of 21.95 TWD, about −87% upside (overvalued).
What is the fair value of 6704?
Our model-based fair value for Gwo Xi Stem Cell Applied Technology Co. , Ltd is 2.93 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 21.95 TWD.
What is the quality score of 6704?
Gwo Xi Stem Cell Applied Technology Co. , Ltd has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Our model-based price target is the fair value of 2.93 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 2.19 TWD, optimistic scenario 4.38 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Gwo Xi Stem Cell Applied Technology Co. , Ltd stock forecast for 2026?
Our models put fair value at 2.93 TWD, about −87% upside versus a price of 21.95 TWD (overvalued). Cautious scenario 2.19 TWD, optimistic scenario 4.38 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Gwo Xi Stem Cell Applied Technology Co. , Ltd reported trailing-twelve-month revenue of about 187M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gwo Xi Stem Cell Applied Technology Co. , Ltd it is 2.93 TWD per share (as of Sep 24, 2026), against a price of 21.95 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Gwo Xi Stem Cell Applied Technology Co. , Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6704 trades above its calculated fair value: price 21.95 TWD, fair value 2.93 TWD, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6704?
No. The price is what the market pays today (21.95 TWD); the fair value is what the company's own numbers justify (2.93 TWD). For Gwo Xi Stem Cell Applied Technology Co. , Ltd the two are 19.02 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Gwo Xi Stem Cell Applied Technology Co. , Ltd worth?
The market values Gwo Xi Stem Cell Applied Technology Co. , Ltd at about 2.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 21.95 TWD; our models calculate a fair value of 2.93 TWD per share.
What do the bullish and bearish scenarios say about 6704?
Our models span a range for Gwo Xi Stem Cell Applied Technology Co. , Ltd: cautious scenario 2.19 TWD, base 2.93 TWD, optimistic 4.38 TWD per share (as of Sep 24, 2026, price 21.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Balance-sheet figures for Gwo Xi Stem Cell Applied Technology Co. , Ltd (as of Sep 24, 2026): return on equity −13.0%, debt of 0.42 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
Which stocks are comparable to Gwo Xi Stem Cell Applied Technology Co. , Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gwo Xi Stem Cell Applied Technology Co. , Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 21.95 TWD, calculated fair value 2.93 TWD (−87%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6704 calculated?
We run Gwo Xi Stem Cell Applied Technology Co. , Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.93 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Gwo Xi Stem Cell Applied Technology Co. , Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The closing price on Sep 24, 2026 was 21.95 TWD. Our model-based fair value is 2.93 TWD, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gwo Xi Stem Cell Applied Technology Co. , Ltd right now?
The price sits above even our optimistic bull case (4.38 TWD). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.19 TWD to 4.38 TWD) leaves room in how you read the outcome.
Key figures of Gwo Xi Stem Cell Applied Technology Co. , Ltd
How large is the market capitalisation of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The market capitalisation of Gwo Xi Stem Cell Applied Technology Co. , Ltd is 2.1B TWD (≈ $66.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The price-to-sales ratio of Gwo Xi Stem Cell Applied Technology Co. , Ltd is 10.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Earnings per share at Gwo Xi Stem Cell Applied Technology Co. , Ltd are −0.8400 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The net margin of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −43.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The return on equity (ROE) of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −13.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
On an EBIT basis the return on assets of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The operating margin of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −45.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Revenue at Gwo Xi Stem Cell Applied Technology Co. , Ltd is growing +2.3% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) generate?
The free cash flow of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −80.7M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) carry?
The net debt of Gwo Xi Stem Cell Applied Technology Co. , Ltd is 129M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Gwo Xi Stem Cell Applied Technology Co. , Ltd in the live analysis
One click puts Gwo Xi Stem Cell Applied Technology Co. , Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
